Role of Systematic Biopsy in the Era of Targeted Biopsy: A Review.

Prostate cancer (PCa) is a major public health issue, as the second most common cancer and the fifth leading cause of cancer-related deaths among men. Many PCa cases are indolent and pose minimal risk, making active surveillance a suitable management approach. However, clinically significant prostat...

Descripción completa

Detalles Bibliográficos
Publicado en:Current Oncology Vol. 31; no. 9; pp. 5171 - 5195
Autores principales: Malewski, Wojciech, Milecki, Tomasz, Tayara, Omar, Poletajew, Sławomir, Kryst, Piotr, Tokarczyk, Andrzej, Nyk, Łukasz
Formato: Journal Article
Publicado: MDPI Sep2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=179965628&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 179965628
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: Sep2024
      vid: 31
      iid: 9
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        179965628
        10.3390/curroncol31090383
        179965628
      ppf: 5171
      ppct: 24
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Role of Systematic Biopsy in the Era of Targeted Biopsy: A Review.
      aug:
        au:
          Malewski, Wojciech
          Milecki, Tomasz
          Tayara, Omar
          Poletajew, Sławomir
          Kryst, Piotr
          Tokarczyk, Andrzej
          Nyk, Łukasz
        affil: Second Department of Urology, Centre of Postgraduate Medical Education, 02-511 Warsaw, Poland
      sug:
      ab: Prostate cancer (PCa) is a major public health issue, as the second most common cancer and the fifth leading cause of cancer-related deaths among men. Many PCa cases are indolent and pose minimal risk, making active surveillance a suitable management approach. However, clinically significant prostate carcinoma (csPCa) can lead to serious health issues, including progression, metastasis, and death. Differentiating between insignificant prostate cancer (inPCa) and csPCa is crucial for determining appropriate treatment. Diagnosis of PCa primarily involves trans-perineal and transrectal systematic biopsies. Systematic transrectal prostate biopsy, which typically collects 10–12 tissue samples, is a standard method, but it can miss csPCa and is associated with some complications. Recent advancements, such as magnetic resonance imaging (MRI)-targeted biopsies, have been suggested to improve risk stratification and reduce overtreatment of inPCa and undertreatment of csPCa, thereby enhancing patient quality of life and treatment outcomes. Guided biopsies are increasingly recommended for their ability to better detect high-risk cancers while reducing identification of low-risk cases. MRI-targeted biopsies, especially when used as an initial biopsy in biopsy-naïve patients and those under active surveillance, have become more common. Utilization of MRI-TB alone can decrease septic complications; however, the combining of targeted biopsies with perilesional sampling is recommended for optimal detection of csPCa. Future advancements in imaging and biopsy techniques, including AI-augmented lesion detection and robotic-assisted sampling, promise to further improve the accuracy and effectiveness of PCa detection.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N